Obinutuzumab treatment of novel dlbcl patient subgroup

TW202637601APending Publication Date: 2026-09-16F HOFFMANN LA ROCHE & CO AG +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114145451
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-08-08
Filing Date
2018-08-08
Publication Date
2026-09-16

Smart Images

  • Figure TWG2TA001076470_001
    Figure TWG2TA001076470_001
  • Figure TWG2TA001076470_002
    Figure TWG2TA001076470_002
  • Figure TWG2TA001076470_003
    Figure TWG2TA001076470_003
Patent Text Reader

Abstract

The present invention relates to obinutuzumab (or its functional equivalents) for use in the treatment of a particular biomarker-defined DLBCL patient and a novel DLBCL patient subgroup, respectively. The present invention further relates to a method for treating DLBCL with obinutuzumab (or its functional equivalents) in a patient in need thereof, wherein said patient is a particular biomarker-defined DLBCL patient or belongs to a novel biomarker-defined DLBCL patient subgroup. The present invention further relates to the use of obinutuzumab (or its functional equivalents) for the preparation of a pharmaceutical composition for the treatment of DLBCL in the particular biomarker-defined DLBCL patient / novel DLBCL patient subgroup. The present invention further relates to a method for identifying a particular DLBCL patient / novel DLBCL patient subgroup and a method for diagnosing a novel form of DLBCL and a particular DLBCL patient / novel DLBCL patient subgroup, respectively.
Need to check novelty before this filing date? Find Prior Art